Looking at recent breakthroughs in CBD science

Cannabis research made some great strides in the 20th century, teaching us lots of critical information about the plant, including the key compounds it produces, and how they impact our overall health by reacting with the endocannabinoid system (ECS).
Establishing that cannabis is a plant of hundreds of compounds which differ from strain to strain has shown us the complexity of the herb, and how certain combinations work better for certain illnesses. This discovery has paved the way for cannabidiol (CBD) products, which are non-psychoactive. As CBD wholesale doesn’t cause a “high” but boasts many unique therapeutic effects, products based around this compound are, for people who would not otherwise be inclined to try cannabis, very appealing.
Indeed, there is a lot of scientific research now carried out on CBD specifically, rather than whole-plant cannabis, which highlight how it could be effective as a solo treatment. In this post, we’ll take a look at the most exciting recent discoveries from that research.
Clinical Endocannabinoid Deficiency (CECD)
Fibromyalgia and migraines are conditions that have proven notorious for medical researchers. The symptoms of both illnesses are unusual, but the number and severity of them has always suggested that there are caused by significant imbalance in the body.
Discovering the ECS may be the most important development in researching treatments for fibromyalgia and migraines, as they look to be a result of deficiency in the system.
This theory is not yet backed by clinical evidence, but scientists forming and building on the concept of CECD are increasingly confident that they have found the root causes of these conditions. For instance, fibromyalgia brings about increased pain and irregular mood patterns. This could be due to dysregulation at the CB1 receptor, and can be corrected by anandamide-mediated activation of it. CBD is anandamide reuptake inhibitor, and this action increases concentrations of the endocannabinoid in the body.
Researchers have also linked the ‘aura’ symptoms of a migraine, which cause increased sensitivity to sound and light, to CB1 receptor dysregulation.
A study has already found that a cannabinoid-based migraine treatment with equal amounts of CBD and THC is as effective as a pharmaceutical migraine drug, with fewer side effects. A similar trial on the medicinal value of CBD in comparison to a commonly-prescribed fibromyalgia drug would also be very useful.
CBD and depression
Depression research has struggled on at a snail’s pace, largely because scientists have focussed on the serotonin neurotransmitter when developing drugs. Serotonin is known for its effect on wellbeing and happiness, but we are not completely sure of its function, or if inhibiting reuptake of the chemical, which SSRI antidepressants do, is the most efficient way of treating depression. Indeed, that one in three patients do not respond to these drugs indicates that it may not be.
Recent brain scans have found that those who suffer from severe depression have often experienced structural changes to the brain as a result of inflammation. However, CBD can help to reverse these changes, by stimulating neurogenesis in affected regions, and by repairing neuronal circuitry.
In the hippocampus, both CBD and another non-psychoactive cannabinoid found in hemp-derived CBD products, cannabichromene (CBC) has been shown to stimulate neuronal growth in the hippocampus.
The ECS also helps to regulate cognition, and this is made possible by the abundance of CB1 receptors in the hippocampus. Keeping this section of the brain healthy is essential for maintaining good memory with age, and reudcing the risk of Alzheimer’s and other neurodegenerative diseases.
Furthermore, CBD may be a more efficient and economical way of managing depression than SSRIs, because the benefits can be observed from the first treatment. A 2018 survey revealed that almost one in six people take CBD to self-medicate their depression.
CBD and autoimmune disease
Psoriasis, rheumatoid arthritis and inflammatory bowel disease (IBD) are all examples of autoimmune diseases, which lead to abnormally low or high activity in the immune system. This either leaves the body exposed to illness, or causes unnecessarily high inflammation which damages the body, sometimes irreversibly.
Regulating the immune system is a difficult task, but the recently unearthed connection between the immune system and the ECS has made cannabinoids a viable treatment option, and non-psychoactive CBD in particular.
CBD is a CB2 receptor antagonist, but sends immunomodulatory signals by propping up anandamide levels in the body. CBD may also help to prevent inflammation by reducing the permeability of gut walls.
CBD edibles wholesale are good products for treating inflammation and autoimmune diseases, as CBD molecules must pass through the gut when taken orally.


Comments are closed.